Key result
P-selectin inhibition with high-dose SLe(x)-OS or combination therapy suppresses cyclic flow variations in injured coronary arteries.
Why the study?
The adhesive interaction between P-selectin and sialyl Lewis X is implicated in the pathophysiology of acute coronary syndromes and cyclic flow variations.
Does inhibition of P-selectin and SLe(x) interaction reduce cyclic flow variations in a canine model of stenosed and endothelium-injured coronary arteries?
Does inhibition of P-selectin and SLe(x) interaction reduce cyclic flow variations in a canine model of stenosed and endothelium-injured coronary arteries?
Inhibition of the adhesive interaction between P-selectin and SLe(x) reduces cyclic flow variations in a canine model of coronary stenosis and endothelial injury.
Hypothesis-generating for selectin inhibition in coronary thrombosis; human trials required before any clinical translation.
BACKGROUND: A fundamental role of cell adhesion molecules is implicated in the disease processes of acute coronary syndromes. We have shown an increase in the soluble form of P-selectin in these syndromes, suggesting the important interaction between P-selectin and sialyl Lewis X (SLe(x)) for the pathophysiology of these syndromes. To further test this, we examined the effects of a monoclonal antibody against P-selectin (PB1.3) and a carbohydrate analogue of SLe(x) (SLe(x)-OS) on cyclic flow variations (CFVs) in stenosed and endothelium-injured canine coronary arteries. METHODS AND RESULTS: Anesthetized, open-chest dogs (n = 48) were divided into six groups after CFVs were established. Dogs received intravenous normal saline, PB1.3 (1 mg/kg bolus), a low dose (5 mg/kg bolus) or a high dose (40 mg/kg bolus) of SLe(x)-OS followed by an infusion (5 mg.kg-1.h-1) for 60 minutes, a combination of PB1.3 and SLe(x)-OS (low dose), or a combination of a nonblocking antibody against P-selectin (PNB1.6, 1 mg/kg) and SLe(x)-OS (low dose). Although saline, PB1.3, SLe(x)-OS (low dose), and the combination of PNB1.6 and SLe(x)-OS (low dose) did not affect CFVs, the high dose of SLe(x)-OS and the combination of PB1.3 and SLe(x)-OS (low dose) significantly reduced CFVs. CONCLUSIONS: These findings indicate that the high dose of SLe(x)-OS and the combination of PB1.3 and the low dose of SLe(x)-OS provide protection against CFVs. Thus, the adhesive interaction between P-selectin and SLe(x) may play an important role in mediating CFVs in this model.
No takes yet. Share an insight, caveat, or question.
Ueyama et al. (1997) studied Cyclic flow variations in stenosed and endothelium-injured coronary arteries (n=48). Monoclonal antibody against P-selectin (PB1.3) and SLe(x)-OS vs. Normal saline or nonblocking antibody (PNB1.6) + SLe(x)-OS (low dose) was evaluated on Cyclic flow variations (CFVs). A high dose of SLe(x)-OS and the combination of PB1.3 with a low dose of SLe(x)-OS significantly reduced cyclic flow variations in stenosed and endothelium-injured canine coronary arteries.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: